Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for fms- like tyrosine kinase- 1
Most Correlated Studies
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
Most Relevant Literature
- Vascular Endothelial Growth Factor Receptor 1 Targeting Fusion Polypeptides with Stimuli-Responsiven…
- Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression …
- Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VE…
- HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting …
- VEGFR1 primes a unique cohort of dental pulp stem cells for vasculogenic differentiation.
Most Relevant Clinical Trials
- PREPARE, Prematurity Reduction by Pre-eclampsia Care
- A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment …
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults F…
- Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FL…
- A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolida…
